Login to Your Account



Orexigen, Arena Shares Benefit

FDA Review Spurs Confidence in Qnexa Despite Safety Issues

By Donna Young


Wednesday, July 14, 2010
WASHINGTON – While the FDA determined that Vivus Inc.'s obesity pill Qnexa (phentermine/topiramate) met the agency's 2007 criteria for efficacy in weight loss, regulators said teratogenicity, along with metabolic acidosis and adverse psychiatric, cognitive and cardiovascular events were concerns of "particular interest" with the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription